SELLAS Life Sciences Group, Inc.

SLS Healthcare Biotechnology

SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

9.98 1.36 −11.99%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−10.0×
Dividend yield
—
F-score
2/9
Altman Z
−16.75
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
18.29 16.60 10.25 7.50
Current Ratio
18.83 17.22 10.72 8.28
Net Debt/EBITDA
13.03 11.59 8.71 6.27
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.79 1.05 0.64 1.04
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.01 0.02 0.02 0.04
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.04) (0.05) (0.05) (0.07)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.04) (0.05) (0.05) (0.07)
Cash per Share
0.73 0.62 0.66 0.41
Shareholders Equity per Share
0.73 0.62 0.65 0.42
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.73 0.62 0.65 0.42
Free Cash Flow
(7.59) (8.85) (4.92) (7.07)
Working Capital
134.94 104.71 68.19 43.13
Net Current Asset Value
134.78 104.40 67.74 43.13
Other line items
Average Payables
3.21 3.69 3.22 3.43
Average Assets
88.84 74.57 48.89 39.03
Average Common Equity
81.90 67.59 40.17 30.76

Fold the line items

Columns are period end dates